Featured Research

from universities, journals, and other organizations

No benefit of double dose antiviral drug for severe influenza, study suggests

Date:
May 30, 2013
Source:
BMJ-British Medical Journal
Summary:
There are no virological or clinical benefits of giving double doses of the antiviral drug oseltamivir (Tamiflu) to patients admitted to hospital with severe influenza, finds a large study from South East Asia.

This is the first study to examine the effectiveness of higher doses of oseltamivir in cases of hospitalized severe human influenza (seasonal, pandemic and bird flu strains). The authors say their findings have implications for global guidelines, clinical management and pandemic preparedness, including for the current H7N9 outbreak.

Related Articles


Human influenza is usually a self-limiting illness. Occasionally, however, it can lead to respiratory complications, admission to hospital, and death. Some studies suggest that, if given early, oseltamivir can help reduce mortality. This has led to suggestions to use double doses of the drug for severe influenza.

So researchers at the South East Asian Infectious Disease Clinical Research Network investigated whether double dose oseltamivir improves outcomes compared with the standard dose in patients admitted to hospital with severe influenza.

The study took place between April 2007 and February 2010 and involved 326 patients (mostly children aged under 15) with severe influenza at 13 hospitals in Indonesia, Singapore, Thailand and Vietnam.

Patients received either standard dose oseltamivir (75 mg twice a day or children's equivalent) or double dose (150 mg twice a day or children's equivalent) for five days. Nose and throat swabs were then taken to test for virus levels.

Other outcomes including death, admission to intensive care, and help with breathing (mechanical ventilation) were also assessed.

The researchers found no differences between the treatment groups in virus levels on day five. There were also no differences in deaths or rates of adverse events between the different doses.

The investigators say that the results "do not support routine use of double dose oseltamivir to treat severe influenza." And they conclude: "There are no virological or clinical advantages with double dose oseltamivir compared with standard dose in patients with severe influenza admitted to hospital."

In an accompanying editorial, Ian Barr and Aeron Hurt from the WHO Collaborating Centre for Reference and Research on Influenza say, despite some study limitations, what is clear is that double dose oseltamivir "is unlikely to significantly improve the clinical outcomes of severe cases of seasonal influenza."

These findings "could help to preserve oseltamivir stocks during a future pandemic … if clinicians were to prescribe only regular rather than double doses," they add. However, they stress that treatment options for patients with severe influenza "still need to be expanded" and that future studies "will hopefully lead to more effective treatments or better combinations of drugs."


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Cite This Page:

BMJ-British Medical Journal. "No benefit of double dose antiviral drug for severe influenza, study suggests." ScienceDaily. ScienceDaily, 30 May 2013. <www.sciencedaily.com/releases/2013/05/130530192427.htm>.
BMJ-British Medical Journal. (2013, May 30). No benefit of double dose antiviral drug for severe influenza, study suggests. ScienceDaily. Retrieved November 26, 2014 from www.sciencedaily.com/releases/2013/05/130530192427.htm
BMJ-British Medical Journal. "No benefit of double dose antiviral drug for severe influenza, study suggests." ScienceDaily. www.sciencedaily.com/releases/2013/05/130530192427.htm (accessed November 26, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, November 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) — The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) — Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com
Madagascar Working to Contain Plague Outbreak

Madagascar Working to Contain Plague Outbreak

AFP (Nov. 24, 2014) — Madagascar said Monday it is trying to contain an outbreak of plague -- similar to the Black Death that swept Medieval Europe -- that has killed 40 people and is spreading to the capital Antananarivo. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com
Are Female Bosses More Likely To Be Depressed?

Are Female Bosses More Likely To Be Depressed?

Newsy (Nov. 24, 2014) — A new study links greater authority with increased depressive symptoms among women in the workplace. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins